Biomarker ID | 1035 |
PMID | 23308129 |
Year | 2013 |
Biomarker | BMI1 |
Biomarker Basis | Concentration Based (ng/mL) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated with Advanced Stage PCa (stage 2: 3.91±.60 Vs Stage 3: 8.55 ±1.95; Stage 4: 10.84 ± 2.44) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: PRC2 complex long-term gene silencing through modification of histone tails, Myc active pathway, Senescence and autophagy, T cell receptor regulation of apoptosis |
Experiment | Stage 2 Vs Stage 3 Vs Stage 4 Prostate Cancer |
Type of Biomarker | Prognostic |
Cohort | 58 human subjects representing normal disease free condition, and different CaP stages, viz., normal (n = 10), Stage II CaP (n=16), Stage III CaP (n=15), and Stage IV CaP (n=17). |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p< 0.001 |
Method Used | Immunohistochemistry; ELISA, western-blot |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |